BRI 2999

Drug Profile

BRI 2999

Alternative Names: BRI2999; SPL 2999

Latest Information Update: 27 Mar 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Biomolecular Research Institute; Cincinnati Childrens Hospital Medical Center; University of Alabama at Birmingham
  • Developer Biomolecular Research Institute; Cincinnati Childrens Hospital Medical Center; Starpharma; University of Alabama at Birmingham
  • Class Antivirals; Dendrimers
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Herpes simplex virus infections

Most Recent Events

  • 09 Feb 2006 No development reported - Preclinical for Herpes simplex virus infections in Australia (Topical)
  • 15 Nov 2002 A preclinical study has been added to the (Service) antimicrobial activity section
  • 01 May 2001 A preclinical study has been added to the Viral Infections antimicrobial activities section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top